NOVOLOG MIX 70/30 Rx
Generic Name and Formulations:
Insulin aspart protamine suspension 70% (rDNA origin), insulin aspart 30% (rDNA origin) 100 Units/mL; SC inj; contains zinc, m-cresol.
Indications for NOVOLOG MIX 70/30:
For SC inj only. Onset approx ≤15 mins, peak approx 2.4hrs, duration up to 24hrs.
During episodes of hypoglycemia.
Do not reuse or share pens between patients; or needles and syringes when using vials. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hypo- or hyperglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Renal or hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia. Do not mix with other insulins.
Hypoglycemia, hypokalemia, local inj site reactions, lipodystrophy, rash, pruritus, edema, sodium retention, weight gain; hypersensitivity and allergic reactions.
Vials (10mL)—1; FlexPen (3mL)—1
Clinical Pain Advisor Articles
- Cannabis Use High in Migraine
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Percutaneous Electrolysis May Be Useful Adjunct for Subacromial Pain Syndrome
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use